Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma

Tétu, Pauline; Mangana, Joanna; Dummer, Reinhard; Dutriaux, Caroline; Beneton, Nathalie; Dalle, Stéphane; Meyer, Nicolas; Oriano, Bastien; Michielin, Olivier; Lebbe, Céleste

doi:10.1016/j.ejca.2018.01.062

Scientific article

Letter

English

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma

ContributorsTétu, Pauline; Mangana, Joanna; Dummer, Reinhard; Dutriaux, Caroline; Beneton, Nathalie; Dalle, Stéphane; Meyer, Nicolas; Oriano, Bastien; Michielin, Olivier

; Lebbe, Céleste

Published inEuropean journal of cancer, vol. 93, p. 147-149

Publication date2018-04

First online date2018-02-12

Keywords

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Follow-Up Studies
Humans
Ipilimumab / administration & dosage
Melanoma / drug therapy
Melanoma / pathology
Nivolumab / administration & dosage
Prognosis
Retrospective Studies
Survival Rate

Affiliation entities

Not a UNIGE publication

Research groups

Découverte de biomarqueurs numériques pour l'oncologie de précision (1059)

Citation (ISO format)

TÉTU, Pauline et al. Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. In: European journal of cancer, 2018, vol. 93, p. 147–149. doi: 10.1016/j.ejca.2018.01.062

Article (Published version)

Identifiers

PID : unige:191532
DOI : 10.1016/j.ejca.2018.01.062
PMID : 29449059

Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S0959804918300765

Journal ISSN0959-8049

4views

0downloads

Creation28/11/2025 17:28:06

First validation16/02/2026 08:19:04

Update16/02/2026 08:19:04

Status update16/02/2026 08:19:04

Last indexation16/02/2026 08:19:06

Archive ouverte UNIGE

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma

Technical informations